Livforsakringsbolaget Skandia Omsesidigt Sells 100 Shares of Amgen Inc. (NASDAQ:AMGN)

Livforsakringsbolaget Skandia Omsesidigt cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,218 shares of the medical research company’s stock after selling 100 shares during the period. Amgen makes up approximately 0.7% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 28th largest holding. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Amgen were worth $12,306,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Capital Performance Advisors LLP bought a new position in Amgen during the third quarter worth about $25,000. Legacy Investment Solutions LLC bought a new position in Amgen during the third quarter worth about $29,000. Matrix Trust Co bought a new position in Amgen during the third quarter worth about $36,000. Heck Capital Advisors LLC bought a new stake in shares of Amgen in the fourth quarter valued at about $36,000. Finally, Livelsberger Financial Advisory bought a new stake in shares of Amgen in the third quarter valued at about $56,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Down 3.3 %

Shares of AMGN stock opened at $297.78 on Friday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock has a market cap of $160.07 billion, a P/E ratio of 38.13, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56. The stock has a 50 day simple moving average of $271.69 and a 200 day simple moving average of $303.55. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. On average, research analysts predict that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.20%. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is 126.09%.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.69% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 price target on shares of Amgen in a report on Thursday, January 2nd. Deutsche Bank Aktiengesellschaft cut their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Wolfe Research assumed coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $314.83.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.